Compounds > n-(2-(hydroxyethoxy)methyl)-5-methyluracil
Page last updated: 2024-12-06

n-(2-(hydroxyethoxy)methyl)-5-methyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-(hydroxyethoxy)methyl)-5-methyluracil: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72358
CHEMBL ID11762
SCHEMBL ID4088248
MeSH IDM0133858

Synonyms (22)

Synonym
acyclothymidine
1-(2-hydroxyethoxymethyl)-5-methyl-pyrimidine-2,4-dione
1-[(2-hydroxyethoxy)methyl]-5-methyluracil
68724-11-8
1-[(2-oheto)me]t
1-[(2-hydroxyethoxy)methyl]thymine
CHEMBL11762
1-(2-hydroxyethoxymethyl)-5-methylpyrimidine-2,4-dione
1-(2-hydroxyethoxy)methyl-5-methyluracil
HMS1617P15
AKOS001696902
1-((2-hydroxyethoxy)methyl)-5-methylpyrimidine-2,4(1h,3h)-dione
CCG-117022
n-(2-(hydroxyethoxy)methyl)-5-methyluracil
2,4(1h,3h)-pyrimidinedione, 1-((2-hydroxyethoxy)methyl)-5-methyl-
FT-0641205
1-[(2-hydroxyethoxy)methyl]-5-methyl-2,4(1h,3h)-pyrimidinedione
ATKOZYBRBNGECU-UHFFFAOYSA-N
1-[(2-hydroxyethoxy)-methyl]-5-methyluracil
DTXSID40218849
SCHEMBL4088248
SB59420

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The absorption and pharmacokinetic parameters of 5'-DFUR and its active metabolite 5-FU, after administration of 5'-DFUR in combination with AcyT, were evaluated in the animals."( Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Fukushima, S; Hamada, A; Kawaguchi, T; Morinaga, A; Nakano, M; Saneyoshi, M, 1993)		0.29
" It was expected that AcyT would only inhibit the phosphorolytic degradation of 5'-DFUR to 5-FU, but the effect was more evident on the pharmacokinetic parameters of 5-FU than on those of 5'-DFUR."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996)		0.29

Bioavailability

ExcerptReferenceRelevance
" AcyT increased the maximal plasma concentration (Cmax) and apparent absorption rate constant (ka) of 5'-DFUR, as expected, but the increase in AUC (area under the curve) was not significant."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID156686Inhibitory concentration required to reduce incorporation of 2-deoxyuridine (dUrd) into DNA of Primary Rabbit kidney (PRK) cell cultures1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID84604Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID293541Antibacterial activity against Proteus vulgaris up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID293540Antibacterial activity against Escherichia coli up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID157570Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-1(strain LAV).1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes.
AID293539Antibacterial activity against Salmonella Typhimurium up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID96829Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID293531Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by MABA2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID156685Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID68999In vitro inhibition of Escherichia coli K-12 growth.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Synthesis and biological effects of acyclic pyrimidine nucleoside analogues.
AID293536Antibacterial activity against Enterococcus faecalis up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID293537Antibacterial activity against Bacillus subtilis up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID217829Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID216388Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID293534Antibacterial activity against Staphylococcus aureus up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID96827Inhibitory concentration required to reduce [3H1',2']dUrd incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID217744The compound was tested for toxicity in Vero cells.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes.
AID293532Antimycobacterial activity against Mycobacterium avium ATCC 252912007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID155468The compound was tested for toxicity in peripheral blood mononuclear cells.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes.
AID210707Compound was evaluated for the inhibitory activity against HSV-1 encoded thymidine kinase at 300 uM; Weak substrate for HSV-1 thymidine kinase1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Pyrimidine acyclic nucleosides, 1-[(2-Hydroxyethoxy)methyl]pyrimidines as candidate antivirals.
AID217434Antiviral activity against Vero cells, infected with HSV-1.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes.
AID85558Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID293535Antibacterial activity against Staphylococcus epidermidis up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID293530Antimycobacterial activity against Mycobacterium bovis BCG by MABA2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID293542Antibacterial activity against Pseudomonas aeruginosa up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID96826Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID293538Antibacterial activity against Streptococcus pneumoniae up to 100 ug/ml after 16 to 20 hrs by broth microdilution method2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Studies on acyclic pyrimidines as inhibitors of mycobacteria.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (30.00)18.7374
1990's6 (30.00)18.2507
2000's3 (15.00)29.6817
2010's5 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		3.87120pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.6930nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		3.4880nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		2.6730organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0310pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
cytarabine
[no description available]		2.0310beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.940organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9710azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		2.03106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
[no description available]		2.0310
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		1.9710aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
thymine arabinoside
thymine arabinoside: selectively inhibits replication of herpes simplex virus		2.0310N-glycosyl compound
edoxudin
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
1,3-dimethyluracil
1,3-dimethyluracil : A pyrimidone that is uracil with methyl group substituents at positions 1 and 3.		1.9610pyrimidonemetabolite
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil: structure given in first source		3.2360
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.0310macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
5-hydroxymethyl-2'-deoxyuridine
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
msh release-inhibiting hormone
[no description available]		2.0310oligopeptide
5-hydroxy-2'-deoxyuridine
5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine		2.0310
5-formyl-2'-deoxyuridine
5-formyl-2'-deoxyuridine: structure given in first source		2.0310
nitrobenzylthioinosine 5'-monophosphate
nitrobenzylthioinosine 5'-monophosphate: RN given refers to parent cpd		1.9710
5-nitro-2'-deoxyuridine
[no description available]		2.0310
5-vinyl-2'-deoxyuridine
5-vinyl-2'-deoxyuridine: structure		2.0310
5-propyl-2'-deoxyuridine
5-propyl-2'-deoxyuridine: RN given refers to parent cpd		2.0310
adenosine-5'-carboxaldehyde
adenosine-5'-carboxaldehyde: potent inhibitor of S-adenosyl-L-homocysteine hydrolase; structure given in first source. 5'-dehydroadenosine : A member of the class of adenosines that is 5'-dehydro derivative of adenosine.		2.0310adenosines
brivudine
brivudine: anti-herpes agent		2.3920
5-ethynyl-2'-deoxyuridine
5-ethynyl-2'-deoxyuridine: structure in first source		2.0310
5-cyano-2'-deoxyuridine
5-cyano-2'-deoxyuridine: structure in first source		2.0310
thioinosine
Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)		1.9710
5-(2-iodovinyl)-2'-deoxyuridine
[no description available]		2.0310
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.39202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		1.9710guanosines;
purines D-ribonucleoside		fundamental metabolite
inosine
[no description available]		1.9710inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0310cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
9-((2-phosphonylmethoxy)ethyl)guanine
9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source		2.0310phosphoethanolamine
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.8840
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Malignant Melanoma
[description not available]		02.1110
Cancer of Skin
[description not available]		02.1110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1110
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		01.9910
Cancer of Lung
[description not available]		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710
Experimental Neoplasms
[description not available]		01.9610